Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
89Zr-13A7Ab
- Development stage
- Preclinical
- Lead developer
- Michigan State University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
89Zr-13A7Ab is a zirconium-89 (89Zr) radiolabeled monoclonal antibody developed by researchers at Michigan State University. It consists of the novel monoclonal antibody 13A7, which targets carbohydrate antigen 19-9 (CA19-9, also known as sialyl Lewis A), conjugated to the positron-emitting radioisotope zirconium-89. CA19-9 is a tumor-associated carbohydrate antigen that is highly overexpressed in pancreatic ductal adenocarcinoma (PDAC) and other malignancies. 89Zr-13A7Ab is utilized as a diagnostic positron emission tomography (PET) imaging tracer to visualize and evaluate CA19-9 expression, tumor accumulation, and pharmacokinetics in pancreatic cancer models, serving as a companion diagnostic or imaging probe for CA19-9-targeted therapies.
- Other names
- 89Zr-labeled 13A789Zr-labeled 13A7 antibody89Zr-labeled 13A7Abzirconium-89-labeled 13A7 antibodyzirconium89-labeled 13A7 antibodyzirconium 89-labeled 13A7 antibody
Beyond the preview
Go deeper on 89Zr-13A7Ab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 89Zr-13A7Ab.